Qi, Huimeng <br/><br/>
miR-150 inhibitor ameliorates adriamycin-induced focal segmental glomerulosclerosis.  [electronic resource] 

 -  Biochemical and biophysical research communications  02 2020 
 - 618-625 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1090-2104 
<br/><br/><label>Standard No.: </label>10.1016/j.bbrc.2019.11.096  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Doxorubicin--adverse effects<br/>Fibrosis<br/>Genetic Therapy<br/>Glomerulosclerosis, Focal Segmental--chemically induced<br/>Humans<br/>Kidney--metabolism<br/>Mice<br/>Mice, Inbred BALB C<br/>MicroRNAs--antagonists & inhibitors<br/>Oligonucleotides--therapeutic use